OrthoPediatrics Corp. (KIDS)
| Market Cap | 565.28M +24.6% |
| Revenue (ttm) | 252.72M +14.5% |
| Net Income | -39.73M |
| EPS | -1.67 |
| Shares Out | 26.11M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 135,532 |
| Open | 21.70 |
| Previous Close | 21.76 |
| Day's Range | 21.26 - 22.17 |
| 52-Week Range | 14.42 - 26.74 |
| Beta | 0.99 |
| Analysts | Buy |
| Price Target | 27.22 (+25.73%) |
| Est. Earnings | Oct 27, 2026 |
About KIDS
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity in children; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruct... [Read more]
Financial Performance
In 2025, OrthoPediatrics's revenue was $236.35 million, an increase of 15.45% compared to the previous year's $204.73 million. Losses were -$39.65 million, 4.83% more than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for KIDS stock is "Buy." The 12-month stock price target is $27.22, which is an increase of 25.73% from the latest price.
News
OrthoPediatrics Expands Its Lower Extremity Bracing Portfolio with the Launch of OPSB® Knee 'TractorFIX
WARSAW, Ind., Oct. 07, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics...
OrthoPediatrics Sponsors the 10th Pediatric Orthopedic Surgical Techniques Course
Milestone program with record attendance brought together 39 participants from 23 institutions across 22 cities and three countries Milestone program with record attendance brought together 39 partici...
OrthoPediatrics Surpasses 1,000 PNP Tibia Nail Implantations
WARSAW, Ind., Sept. 22, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedic...
OrthoPediatrics Announces Full Commercial Launch of 3P™ Pediatric Plating Platform® Hip System Following More Than 350 Successful Implantations
Successful Limited Launch Demonstrates Demand for Innovative Pediatric-Specific Hip Plating Technology Successful Limited Launch Demonstrates Demand for Innovative Pediatric-Specific Hip Plating Techn...
OrthoPediatrics price target raised to $29 from $24 at BTIG
BTIG raised the firm’s price target on OrthoPediatrics (KIDS) to $29 from $24 and keeps a Buy rating on the shares as part of a broader research note updating the…
OrthoPediatrics Transcript: Canaccord Genuity's 46th Annual Growth Conference
Record Q2 results and raised guidance highlight a pivotal inflection point, driven by innovative product launches, improved asset utilization, and strong international growth. The business is set for continued profitability, with a robust pipeline and favorable competitive dynamics.
OrthoPediatrics price target raised to $22 from $20 at Truist
Truist analyst Richard Newitter raised the firm’s price target on OrthoPediatrics (KIDS) to $22 from $20 and keeps a Hold rating on the shares. OrthoPediatrics delivered a strong Q2 beat…
OrthoPediatrics price target raised to $25 from $22 at Piper Sandler
Piper Sandler analyst Matt O’Brien raised the firm’s price target on OrthoPediatrics (KIDS) to $25 from $22 and keeps an Overweight rating on the shares. The firm notes the company…
OrthoPediatrics price target raised to $28 from $25 at Canaccord
Canaccord raised the firm’s price target on OrthoPediatrics (KIDS) to $28 from $25 and keeps a Buy rating on the shares. The firm said they posted a strong Q2 revenue…
OrthoPediatrics price target raised to $24 from $22 at Stifel
Stifel raised the firm’s price target on OrthoPediatrics (KIDS) to $24 from $22 and keeps a Buy rating on the shares.
OrthoPediatrics Earnings Call Transcript: Q2 2026
Record Q2 revenue and adjusted EBITDA were driven by strong T&D and OPSB growth, improved margins, and disciplined capital allocation. Raised full-year guidance reflects confidence in continued momentum, with new product launches and international expansion expected to drive durable growth.
OrthoPediatrics Earnings release: Q2 2026
OrthoPediatrics released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
OrthoPediatrics Quarterly report: Q2 2026
OrthoPediatrics has published its Q2 2026 quarterly earnings report on August 4, 2026.
OrthoPediatrics Corp. Reports Second Quarter 2026 Financial Results and Increases 2026 Financial Guidance
WARSAW, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics...
OrthoPediatrics to Participate in the Canaccord Genuity 46th Annual Growth Conference
WARSAW, Ind., July 29, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics...
OrthoPediatrics Corp. to Report Second Quarter Financial Results on August 4, 2026
WARSAW, Ind., July 21, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics...
OrthoPediatrics Announces Distribution Agreement with OSSIO, Inc. to Provide Revolutionary Orthopedic Fixation Technology to U.S. Children's Hospitals Nationwide
WARSAW, Ind., June 24, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics...
OrthoPediatrics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Focused on pediatric orthopedics, the business is experiencing strong growth, driven by a robust new product pipeline, international expansion, and disciplined financial management. Recent regulatory approvals and acquisitions support margin and cash flow improvements, with a clear path to free cash flow breakeven by 2026.
OrthoPediatrics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
WARSAW, Ind., May 26, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics,...
OrthoPediatrics price target lowered to $17 from $20 at Truist
Truist lowered the firm’s price target on OrthoPediatrics (KIDS) to $17 from $20 and keeps a Hold rating on the shares. The firm notes that sales upside relative to consensus…
OrthoPediatrics expands specialty bracing portfolio with Traxio launch
OrthoPediatrics (KIDS) announced the launch of the Traxio Complete Weight System, in collaboration with Synetik Group, Inc. “The introduction of TRAXIO reflects our ongoing commitment to advancing ped...
OrthoPediatrics reports Q1 EPS (42c), consensus (48c)
Reports Q1 revenue $59.36M, consensus $58.32M. David Bailey, President & CEO of OrthoPediatrics (KIDS), commented, “We delivered a strong start to 2026 with 13% first quarter revenue growth and signif...
OrthoPediatrics sees FY26 revenue $263M-$267M, consensus $264.31M
Previous view was $262M-$266M.
OrthoPediatrics Earnings Call Transcript: Q1 2026
Q1 2026 saw 13% revenue growth, strong international and OPSB expansion, and improved profitability. Guidance was raised for 2026, with new product launches and regulatory wins expected to drive further growth and margin expansion.
OrthoPediatrics Earnings release: Q1 2026
OrthoPediatrics released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.